These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9877002)

  • 21. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
    Nelson HS
    J Allergy Clin Immunol; 2001 Feb; 107(2):398-416. PubMed ID: 11174215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Brogden RN; Faulds D
    Drugs; 1991 Nov; 42(5):895-912. PubMed ID: 1723379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence based answers--is salmeterol safe in asthma?
    Spurling G; Doust J
    Aust Fam Physician; 2006 Aug; 35(8):625-6. PubMed ID: 16894440
    [No Abstract]   [Full Text] [Related]  

  • 24. Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.
    Lindmark B
    Ther Adv Respir Dis; 2008 Oct; 2(5):279-99. PubMed ID: 19124378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology.
    J Allergy Clin Immunol; 1996 Sep; 98(3):475-80. PubMed ID: 8828522
    [No Abstract]   [Full Text] [Related]  

  • 26. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.
    Adkins JC; McTavish D
    Drugs; 1997 Aug; 54(2):331-54. PubMed ID: 9257086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.
    Peters S
    Curr Med Res Opin; 2007 Sep; 23 Suppl 3():S29-36. PubMed ID: 17925066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-adrenergic receptor genotype and response to salmeterol.
    Wechsler ME; Israel E
    J Allergy Clin Immunol; 2007 Jul; 120(1):218-9; author reply 219-20. PubMed ID: 17399776
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacological action and clinical aspects of salmeterol].
    Oguri K
    Nihon Yakurigaku Zasshi; 2003 Sep; 122(3):265-70. PubMed ID: 12939544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
    Goleva E; Dunlap A; Leung DY
    J Allergy Clin Immunol; 2004 Jul; 114(1):183-91. PubMed ID: 15241363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of long-acting beta-agonists.
    Johnson M
    Ann Allergy Asthma Immunol; 1995 Aug; 75(2):177-9. PubMed ID: 7648384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-acting beta2-agonist bronchodilators safety for asthma treatment].
    Giubergia V
    Arch Argent Pediatr; 2009 Aug; 107(4):291-3. PubMed ID: 19753432
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma.
    Löfdahl CG; Chung KF
    Eur Respir J; 1991 Feb; 4(2):218-26. PubMed ID: 1675178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A word of caution regarding a new long-acting bronchodilator.
    Bone RC
    JAMA; 1994 May; 271(18):1447-8. PubMed ID: 7909854
    [No Abstract]   [Full Text] [Related]  

  • 35. New possibilities for the beta-adrenoceptor agonist bronchodilator drugs.
    Waldeck B; Olsson OA; Svensson LA
    Agents Actions Suppl; 1988; 23():55-68. PubMed ID: 2902766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains.
    Baker JG; Proudman RG; Hill SJ
    Mol Pharmacol; 2015 Jan; 87(1):103-20. PubMed ID: 25324048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the tolerance to the bronchoprotective effect of salmeterol clinically relevant?
    Nathan RA
    Ann Allergy Asthma Immunol; 1998 Jan; 80(1):1-3; discussion 4. PubMed ID: 9475559
    [No Abstract]   [Full Text] [Related]  

  • 38. [Salmeterol, a new long-acting beta 2-agonist in asthma treatment].
    Chyrek-Borowska S; Kowal K
    Pol Merkur Lekarski; 1997 Oct; 3(16):160-2. PubMed ID: 9461719
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of asthma with salmeterol--a new prolonged-action inhalatory beta 2 agonist].
    Dahl R; Pedersen B
    Ugeskr Laeger; 1991 Oct; 153(44):3098-100. PubMed ID: 1683037
    [No Abstract]   [Full Text] [Related]  

  • 40. Respiratory pharmacology. Beta-adrenergic drugs.
    Popa V
    Clin Chest Med; 1986 Sep; 7(3):313-29. PubMed ID: 2876798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.